Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price traded up 25.6% during trading on Monday . The company traded as high as C$0.27 and last traded at C$0.25. 1,195,705 shares were traded during mid-day trading, an increase of 194% from the average session volume of 407,275 shares. The stock had previously closed at C$0.20.
Theralase Technologies Price Performance
The firm has a market capitalization of C$75.50 million, a price-to-earnings ratio of -15.83 and a beta of -0.35. The stock’s fifty day moving average price is C$0.17 and its two-hundred day moving average price is C$0.19. The company has a current ratio of 1.91, a quick ratio of 3.40 and a debt-to-equity ratio of 14.85.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Stories
- Five stocks we like better than Theralase Technologies
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- The $100 Trillion AI Story No One Is Telling You
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- End of America update
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
